Safety and Efficacy of Combined High-Dose Treatment with Calcipotriol Ointment and Solution in Patients with Psoriasis

Dermatology ◽  
2002 ◽  
Vol 204 (3) ◽  
pp. 214-221 ◽  
Author(s):  
P.C.M. van de Kerkhof ◽  
C. Green ◽  
K.J. Hamberg ◽  
P.E. Hutchinson ◽  
J.K. Jensen ◽  
...  
Keyword(s):  
High Dose ◽  
Safety And Efficacy ◽  
Dose Treatment ◽  
High Dose Treatment

P162 clinical pharmacokinetics of etoposide during high-dose treatment in relation to toxicity

1994 ◽  
Vol 2 (1-2) ◽  
pp. 159
Author(s):  
S. Stremetzne ◽  
U. Jaehde ◽  
J. Beyer ◽  
J. Steuer ◽  
W. Siegert ◽  
...  
Keyword(s):  
High Dose ◽  
Clinical Pharmacokinetics ◽  
Dose Treatment ◽  
High Dose Treatment

Clinical use of High-Dose Neuroleptics

1994 ◽  
Vol 164 (1) ◽  
pp. 94-96 ◽  
Author(s):  
Steven R. Hirsch ◽  
Thomas R. E. Barnes
Keyword(s):  
British National Formulary ◽  
High Dose ◽  
Clinical Use ◽  
National Formulary ◽  
Public Concern ◽  
Neuroleptic Treatment ◽  
Clinical Issues ◽  
Small Minority ◽  
Dose Treatment ◽  
High Dose Treatment

There has been increasing public concern about the risks of high-dose antipsychotic (neuroleptic) treatment, arising in part from an, as yet unproven, association between high-dose treatment and death in a small minority of patients. The clinical issues related to the use of neuroleptics in doses exceeding the maximum recommended in theBritish National Formulary(BNF) were discussed at the Psychopharmacology Subcommittee. When, if ever, should the recommended doses be exceeded?

Phase I study evaluating high-dose treatment with ADXS11-001, a Listeria monocytogenes-listeriolysin O (Lm-LLO) immunotherapy, in women with cervical cancer.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e14580-e14580 ◽  
Author(s):  
Sharad A. Ghamande ◽  
Daniel Platt ◽  
Donna Wheatley ◽  
Bunja Jane Rungruang ◽  
John Edward Janik ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Listeria Monocytogenes ◽  
Phase I ◽  
Phase I Study ◽  
High Dose ◽  
Listeriolysin O ◽  
Dose Treatment ◽  
High Dose Treatment

EFFECT OF REPETITIVE HIGH-DOSE TREATMENT WITH SOLUBLE COMPLEMENT RECEPTOR TYPE 1 AND COBRA VENOM FACTOR ON DISCORDANT XENOGRAFT SURVIVAL1,2

1996 ◽  
Vol 62 (3) ◽  
pp. 336-342 ◽  
Author(s):  
Daniel Candinas ◽  
Beth-Ann Lesnikoski ◽  
Simon C. Robson ◽  
Tsukasa Miyatake ◽  
Susanne M. Scesney ◽  
...  
Keyword(s):  
Receptor Type ◽  
Cobra Venom ◽  
High Dose ◽  
Complement Receptor ◽  
Cobra Venom Factor ◽  
Dose Treatment ◽  
Complement Receptor Type ◽  
High Dose Treatment ◽  
Complement Receptor Type 1
Sign in / Sign up

Export Citation Format

Share Document